Pivanex Treatment for Malignant Melanoma

This study focuses on a drug called Pivanex, which is a histone deacetylase inhibitor. This type of drug helps to slow down or stop the growth of cancer cells and has shown promising results in non-small cell lung cancer. Now, researchers want to see if it can also help patients with malignant melanoma, a serious type of skin cancer. The goal is to find new ways to treat this disease, especially for those who have not responded well to chemotherapy or Interleukin-2 (IL-2). In this study, participants will receive Pivanex through an intravenous (IV) line, which is a small tube inserted into a vein, over a period of 6 hours for 3 days. This treatment cycle will be repeated every 21 days until the cancer progresses or the patient is withdrawn from the study for other reasons. The response to the treatment will be checked before every odd-numbered cycle using a method called the Response Evaluation Criteria in Solid Tumors (RECIST). The study will measure how long it takes for the disease to progress, overall survival, and the safety of using Pivanex for malignant melanoma.